Phase 2 study update: Epcoritamab demonstrates clinically meaningful and compelling efficacy in the treatment of R/R large B-cell lymphoma
New data show that epcoritamab is an effective off-the-shelf therapy for both CAR T-exposed and CAR T-naive patients with R/R LBCL who had already received prior lines of therapy.
